Program - Society of Toxicology

More documents

Recommendations

Info

50 th Anniversary Annual Meeting and ToxExpo Program Description (Continued) Wednesday Abstract # Abstract # 6:55 USE OF PRECISION-CUT LIVER SLICE CULTURES TO STUDY KUPFFER CELL- MEDIATED DRUG TOXICITY. Nandita Shangari 7:05 EX VIVO LUNG CULTURE MODELS TO STUDY RESPIRATORY INFLAMMATION AND THEIR RELEVANCE FOR IN VIVO. Armin Braun 7:15 CROSS-SPECIES COMPARISON ON PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITIES IN PRECISION-CUT LUNG SLICES. Christian Martin 7:25 CROSS-SPECIES COMPARISON OF DRUG METABOLISM AND TOXICITY IN INTESTINAL SLICES. Genny M. Groothuis 7:35 PANEL DISCUSSION/Q&A. Wednesday Morning, March 9 6:30 AM to 7:50 AM Room 150 Toxicity Testing: State of Science and Strategies to Improve Public Health Informational Session: The Application of the Threshold of Toxicological Concern Concept to the Preclinical Safety Assessment of Non-Pharmaceutical Medical Products, Including Medical Devices and Combination Drug-Device Products Chairperson(s): Richard W. Hutchinson, Johnson & Johnson: Ethicon, Somerville, NJ, and Ronald P. Brown, U.S. FDA, Silver Spring, MD. Sponsor: Medical Device Specialty Section Endorsed by: Regulatory and Safety Evaluation Specialty Section Risk Assessment Specialty Section The Threshold of Toxicological Concern (TTC) is a concept used to estimate safe exposure levels for chemicals for which toxicological data are not available. It is based on chemical structure and known safety data for structurally related chemicals. This value represents a low level of exposure with negligible risk to humans. The process for demonstrating preclinical safety or biocompatibility of medical devices often involves a staged approach starting with a thorough understanding of the chemical composition of the device, then progressing through in vitro and in vivo bioassays and ultimately continuing the risk management process through the lifecycle of the product. The TTC concept is a tool that many risk assessors use to make decisions early in this staged process, and international committees are actively developing standardized methods for applying these techniques. In order to adequately explore this topic, we begin by discussing the history of the TTC concept along with an overview of the areas that this concept has been embraced up to this point. We will provide a description of how tolerable intake levels are set for medical device extractables when an adequate database of information about the extracted chemical is known. In addition, information will be provided on how the TTC concept can be used for extractable chemicals from medical devices for which structural information is known but the toxicological database is insufficient. Finally, the validation of a software package in the context of extractable chemicals known to be relevant to medical devices will be described. #1767 6:30 THE APPLICATION OF THE THRESHOLD OF TOXICOLOGICAL CONCERN CONCEPT TO THE PRECLINICAL SAFETY ASSESSMENT OF NON-PHARMACEUTICAL MEDICAL PRODUCTS, INCLUDING MEDICAL DEVICES AND COMBINATION DRUG-DEVICE PRODUCTS. R. W. Hutchinson 1 , R. Brown 2 , M. A. Cheeseman 3 and J. Cammack 4 . 1 Preclinical, Johnson&Johnson: Ethicon, Somerville, NJ, 2 CDRH, U.S. FDA, Silver Spring, MD, 3 CFSAN, U.S. FDA, Riverdale, MD and 4 ISIS Services, San Carlos, CA. 6:30 INTRODUCTION. Richard W. Hutchinson 6:35 HISTORY OF THE THRESHOLD OF TOXICOLOGICAL CONCERN CONCEPT. Mitchell Cheeseman 6:50 USE OF ISO 10993-17 GUIDELINES FOR SETTING TOLERABLE EXPOSURE LIMITS. Jon Cammack 7:05 THRESHOLD OF TOXICOLOGICAL CONCERN: APPLICATION TO MEDICAL DEVICES. Richard W. Hutchinson 7:20 CATEGORIZATION OF COMPOUNDS RELEASED FROM MEDICAL DEVICE MATERIALS INTO CRAMER CLASSES USING TOXTREE SOFTWARE. Ron Brown 7:35 PANEL DISCUSSION/Q&A. Wednesday Morning, March 9 6:30 AM to 7:50 AM Room 144 Education-Career Development Session: From Pilot Grants to High-End Journals: The Science of Writing Chairperson(s): Marie C. Fortin, Environmental and Occupational Health Sciences Institute, Piscataway, NJ, and Anne Loccisano, The Hamner Institutes for Health Sciences, Research Triangle Park, NC. Sponsor: Education Committee Endorsed by: Career Resource and Development Committee Postdoctoral Assembly Student Advisory Council Want to learn how to write effective grants and publications, or sharpen your scientific writing skills to communicate better? As toxicologists, it is essential that we be able to articulate new ideas in the form of grants and to disseminate the results of research in the form of scientific publications. Thus effective communication through writing is fundamental therefore it is crucial for early career scientists to learn effective writing skills. Publishing is imperative in academic or non-profit sectors and obtaining sufficient funding is a necessity when establishing a career and reputation. However, most scientists do not receive any formal training in writing and these skills are usually learned by following the style of a mentor or other authors. This issue is particularly important for graduate students, postdoctoral fellows, and other early career scientists who would like to enhance their critical writing skills which are needed for good communication. Our panel of experts will provide the audience with tactics to write promising NIH grant applications, general approaches that enhance the publication success of scientific papers, as well as concrete scientific writing strategies from an author’s and reader’s standpoint. Attendees will be provided with tips to enhance their skills that will enable more effective communication of both their ideas and their science, from grant proposals to publication. 272 Education-Career Development Sessions Exhibitor Hosted Sessions Featured Sessions Historical Highlights Informational Sessions Platform Sessions
Society of Toxicology 2011 Program Description (Continued) Abstract # #1768 6:30 FROM PILOT GRANTS TO HIGH-END JOURNALS: THE SCIENCE OF WRITING, M. C. Fortin 1 and A. E. Loccisano 2 . 1 Clinical Research and Occupational Medicine, Environmental and Occupational Health Sciences Institute, Piscataway, NJ and 2 The Hamner Institutes for Health Sciences, Research Triangle Park, NC. 6:30 Introduction. Marie Fortin 6:34 Communicating Ideas Efficiently: An Essential Skill for All Researchers. Deborah A. Cory- Slechta 6:53 Grantsmanship at NIH: How to Swim with the Sharks. Jerrold J. Heindel 7:12 Writing for Success. Angela K. Eggleston 7:31 Panel Discussion/Q&A. Wednesday Morning, March 9 8:00 AM to 9:00 AM Grand Ballroom Keynote Medical Research Council (MRC) Lecture: Cellular Responses to DNA Damage: New Molecular Insights and New Approaches for Cancer Therapy Lecturer: Stephen P. Jackson, The Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom. Inherited or acquired defects in detecting, signalling or repairing DNA damage are associated with various human pathologies, including immuno-deficiencies, neurodegenerative diseases and various forms of cancer1. Our increasing knowledge of cellular DNA-damage responses (DDR) is therefore providing new insights into the aetiology of such diseases and, moreover, is presenting opportunities for novel diagnostic and therapeutic strategies. Work in Dr. Jackson’s laboratory aims to decipher the mechanisms by which cells detect DNA damage and signal its presence to the DNA-repair and cell-cycle machineries. In particular, much of the work focuses on DNA double-strand breaks (DSBs) that are generated by ionizing radiation and radiomimetic chemicals, and which can also arise when the DNA replication apparatus encounters other DNA lesions. In this talk, Dr. Jackson will first provide an overview of how cells respond to DNA damage and will describe the key protein players in these events. Next, he will discuss some of our recent work that has identified new proteins that mediate DSB responses, control DSB processing or modulate chromatin structure at DNA damage sites. He will then explain how this type of work identified therapeutic opportunities that led to me founding KuDOS Pharmaceuticals Ltd, whose mission was to develop DDR inhibitors for cancer therapy. Finally, He will use the example of the KuDOS drug olaparib (now owned by and being developed by AstraZeneca) to highlight the exciting potential for DDR inhibitors in treating many cancers. Specifically, Dr. Jackson will explain the molecular basis for how olaparib is exquisitely cytotoxic to cancer cells bearing DSB repair defects because of inherited mutations in BRCA1 or BRCA2 but is well tolerated by normal cells of cancer patients. In closing, he will explain how this and related mechanisms of “synthetic lethality” might be applied to a wider range of cancers that bear DDR defects. Abstract # Wednesday Morning, March 9 9:00 AM to 11:45 AM Room 202A Symposium Session: Autism: Genetic, Epigenetic, and Environmental Factors Influencing Neural Networks Chairperson(s): Isaac Pessah, University of California Davis, Davis, CA, and Cindy Lawler, National Institute of Environmental Health Sciences, Durham, NC. Sponsor: Neurotoxicology Specialty Section Endorsed by: Reproductive and Developmental Toxicology Specialty Section Risk Assessment Specialty Section Our current knowledge about how genetic, epigenetic, and environmental factors contribute to autism susceptibility is ever changing. From a toxicologist’s perspective, the identity of defective genes and signaling pathways linked to autism provide important clues about exposures to environmental chemicals that influence autism susceptibility, severity, and/or treatment outcomes. One fundamental way by which heritable genetic vulnerabilities can amplify the adverse effects triggered by environmental exposures is if both factors (genes x environment) converge to dysregulate the same signaling systems at critical times of development. Thus, we will review current knowledge of genetic contributions to autism risk, and present new evidence that autism is associated with an appreciably increased level of genomic instability in low copy repeat (LCR) rich intervals of the genome and how environmental factors that affect genomic stability could contribute to the incidence and severity of autism. We will highlight new findings from both a mouse model of Rett Syndrome and human tissues that contribute to our understanding of how developmental exposures to brominated flame retardants (PBDEs) influence DNA methylation and neurobehavioral outcomes relevant to autism. An update will be provided on recent progress in understanding how impairments in neural connectivity contribute to autism including seminal findings of the role of MET polymorphisms play in autism risk and how polyaromatic hydrocarbons found in air pollution might influence MET signaling. Finally, we will review the major translational issues confronting autism research and provide information about current funding opportunities in autism research. #1769 9:00 AUTISM: GENETIC, EPIGENETIC, AND ENVIRONMENTAL FACTORS INFLUENCING NEURAL NETWORKS. I. N. Pessah. Department of Molecular and Biological Sciences, University of California Davis, Davis, CA. 9:00 INTRODUCTION. Isaac Pessah #1770 9:15 COPY NUMBER BURDEN ASSOCIATED WITH AUTISM IN UNSTABLE SEGMENTS OF THE GENOME. S. B. Selleck 1,2,7 , R. L. Johnson 2 , J. Balciuniene 7,3 , C. M. Conboy 7 , T. B. Nauth 2 , A. N. Klossner 7 , M. Alsagabi 4 , A. Alqallaf 4 , R. Davis 5 , R. Hansen 5 , J. Gregg 5 , I. Hertz-PIcciotto 5 , A. Tewfik 4 and I. N. Pessah 6,5 . 1 Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, PA, 2 Pediatrics, University of Minnesota, Minneapolis, MN, 3 Biology, Temple University, Philadephia, PA, 4 Electrical Engineering and Computer Science, University of Minnesota, Minneapolis, MN, 5 The Medical Investigations of Neurodevelopmental Disorders Institute, University of California, Davis, Sacramento, CA, 6 Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, CA and 7 Genetics Cell Biology and Development, University of Minnesota, Minneapolis, MN. Wednesday Poster Sessions Regional Interest Session Roundtable Sessions Symposium Sessions Thematic Sessions Workshop Sessions 273
Page 1 and 2:
50 th Anniversary Annual Meeting &
Page 3 and 4:
Scientific Program Overview A page
Page 5 and 6:
9:00 AM-12:30 PM POSTER SESSionS
Page 7 and 8:
March 6-10, 2011 Walter E. Washingt
Page 9 and 10:
Celebration Activities Historical H
Page 11 and 12:
of the Society Regional Chapter Yea
Page 13 and 14:
SOT Presidents 1961-2011 1966 1967
Page 15 and 16:
The SOT Council Thanks and Recogniz
Page 17 and 18:
of the Past 50 Years 2003 Michael D
Page 19 and 20:
Thank You to the following individu
Page 21 and 22:
SOT Celebration Event Floor Plan Ba
Page 23 and 24:
50 th Anniversary Annual Meeting an
Page 25 and 26:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 27 and 28:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 29 and 30:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 31 and 32:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 33 and 34:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 35 and 36:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 37 and 38:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 39 and 40:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 41 and 42:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 43 and 44:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 45 and 46:
Toxicological Sciences The Official
Page 47 and 48:
Society of Toxicology 2011 Walter E
Page 49 and 50:
Society of Toxicology 2011 Washingt
Page 51 and 52:
Society of Toxicology 2011 Map of W
Page 53 and 54:
2011 SOT 50 th Anniversary Featured
Page 55 and 56:
Society of Toxicology 2011 Washingt
Page 57 and 58:
Society of Toxicology 2011 ToxExpo
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Society of Toxicology 2011 Exhibito
Page 65 and 66:
Creating a Safer and Healthier Worl
Page 67 and 68:
Society of Toxicology 2011 General
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
SOT Job Bank YOUR RECRUITMENT AND E
Page 83 and 84:
Society of Toxicology 2011 Career R
Page 85 and 86:
Society of Toxicology 2011 SOT 2011
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Society of Toxicology 2011 2011 Awa
Page 95 and 96:
Endowment Awardees for SOT’s 50 t
Page 97 and 98:
Society of Toxicology 2011 SOT Endo
Page 99 and 100:
Society of Toxicology 2011 Recognit
Page 101 and 102:
Society of Toxicology 2011 Recognit
Page 103 and 104:
Society of Toxicology 2011 RC, SIG,
Page 105 and 106:
Society of Toxicology 2011 Student
Page 107 and 108:
Society of Toxicology 2011 Outreach
Page 109 and 110:
Society of Toxicology 2011 Satellit
Page 111 and 112:
Society of Toxicology 2011 Continui
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Society of Toxicology 2011 Scientif
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Society of Toxicology 2011 Poster S
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Society of Toxicology 2011 Program
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244: Society of Toxicology 2011 Program
Page 293: Society of Toxicology 2011 Program
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Society of Toxicology 2011 Author I
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Society of Toxicology 2011 Abstract
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Society of Toxicology 2011 2010-201
Page 427 and 428:
Society of Toxicology 2011 Elected
Page 429 and 430:
Society of Toxicology 2011 Elected
Page 431 and 432:
Society of Toxicology 2011 Regional
Page 433 and 434:
Society of Toxicology 2011 Specialt
Page 435 and 436:
Society of Toxicology 2011 Specialt
Page 437 and 438:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 439 and 440:
Society of Toxicology 2011 Endowmen
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Society of Toxicology 2011 SOT Affi
Page 449 and 450:
Society of Toxicology 2011 Notes up
Page 451 and 452:
Society of Toxicology 2011 Notes up
Page 453 and 454:
Society of Toxicology 2011 Headquar
Page 455 and 456:
QUICK REFERENCE Visit www.mwata.com
show all

Program - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?